Advertisement

TechCrunch+ roundup: Using predictive LTV, Boston VC survey, active learning for ML teams

Last fall, Voyantis CEO Ido Wiesenberg shared a TC+ post with several tactics for reducing customer acquisition costs via predictive modeling.

In a follow-up, he explains how to use predictive lifetime value (LTV) to create “more targeted, effective acquisition strategies that focus on acquiring and retaining customers.”

Adding predictive LTV to decision flows does more than just identify lucrative customers early in the sales cycle — you can also use it to set performance targets and help teams adjust campaign budgets midstream.


Full TechCrunch+ articles are only available to members.
Use discount code TCPLUSROUNDUP to save 20% off a one- or two-year subscription.


“Not using predictive LTV to inform decisions is like going on a hike, not knowing where it will end and how hard it will be,” writes Wiesenberg, who says combining CAC with predictive LTV optimization balances risk and growth.

ADVERTISEMENT

This post includes real-life examples of predictive LTV decisions that can help generate higher returns on ad spending or identify underperforming campaigns that can be stopped in their tracks.

Thanks very much for reading,

Walter Thompson
Editorial Manager, TechCrunch+
@yourprotagonist

Going private: A guide to PE tech acquisitions

Image of a large fish going after a smaller fish
Image of a large fish going after a smaller fish

Image Credits: PM Images (opens in a new window) / Getty Images

For private equity firms in search of bargains, now is a great time to be alive.

With the IPO window nailed shut and so many public companies facing dwindling valuations, PE firms spent $226.5 billion on M&A in H1 2022, 39% more than a year earlier.

However, "success is not guaranteed," writes Jaggaer CFO Jeff Laborde in a TC+ explainer that examines what happens in the months that follow the pre-closing period.

"M&A is a part of doing business and it’s important to recognize that the impact and disruption of a PE take-private deal may be felt for years."

Biotech proved a surprisingly bright spot in 2022’s startup correction

biotech, fundraising, startups
biotech, fundraising, startups

Image Credits: Getty Images

The hard science and regulations that govern biotech companies sets them far apart from other startups.